Stifel initiated coverage on Ligand Pharma with a new price target
$LGND
Biotechnology: Pharmaceutical Preparations
Health Care
Stifel initiated coverage of Ligand Pharma with a rating of Buy and set a new price target of $143.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/10/2025 | $143.00 | Buy | Stifel |
| 10/3/2024 | $135.00 | Outperform | Oppenheimer |
| 7/30/2024 | $130.00 | Outperform | RBC Capital Mkts |
| 2/22/2022 | $180.00 → $130.00 | Buy | Benchmark |
| 2/18/2022 | $185.00 → $165.00 | Overweight | Barclays |
| 9/22/2021 | $174.00 → $180.00 | Overweight | Barclays |
| 7/30/2021 | $200.00 → $190.00 | Buy | Roth Capital |
JUPITER, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that the company will ring The Nasdaq Stock Market Opening Bell on Monday, May 19, 2025. CEO Todd Davis will be joined by members of Ligand's senior management team and board of directors to commemorate several recent company milestones, including two value-creating transactions. "Ringing the Nasdaq Opening Bell marks an exciting milestone in our company's history. Over the past few years, we have made significant progress in transforming Ligand into a profitable and infrastructure-light organization focused on acquiring and generating royalties from a diverse portfolio of b
First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Creek Biosciences Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share of $6.00-$6.251 Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2025, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8
JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its senior management team will participate in the following upcoming investor conferences: H.C. Wainwright Royalty Company Conference (Virtual). Management will participate in a fireside chat on May 13, 2025 at 3:30 p.m. ET and be available for one-on-one meetings.RBC Capital Markets Global Healthcare Conference (New York). Management will participate in a fireside chat on May 20, 2025 at 2:05 p.m. ET and be available for one-on-one meetings.Craig-Hallum Institutional Investor Conference (Minneapolis). Management will participate in one-on-one meetings on May 28, 2025.
First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Creek Biosciences Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share of $6.00-$6.251 Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2025, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8
JUPITER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report first quarter 2025 financial results before the opening of the U.S. financial markets on Thursday, May 8, 2025. The company will hold a conference call that same day beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast InformationDate: Thursday, May 8, 2025 Time: 8:30 AM Eastern Time Conference Call: (800) 715-9871 (U.S. & Canada) (646) 307-1963 (International) Conference ID 3661098 Webcast: Live and replay webcasts of the call are available here. About Ligand PharmaceuticalsLiga
Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare-dedicated investors, completed transformation to a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic skin diseases Top-line results from SELVA, a Phase 3 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs), on track for the first quarter of 2026 Top-line results from TOIVA, a Phase 2 single-arm, baseline-controlled trial evaluating QTORIN™ rapamycin for the treatment of
SC 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)
SC 13G - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)
SC 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
Stifel initiated coverage of Ligand Pharma with a rating of Buy and set a new price target of $143.00
Oppenheimer initiated coverage of Ligand Pharma with a rating of Outperform and set a new price target of $135.00
RBC Capital Mkts initiated coverage of Ligand Pharma with a rating of Outperform and set a new price target of $130.00
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced the appointment of Matthew E. Korenberg as Chief Financial Officer, effective immediately. Mr. Korenberg is a seasoned operational and financial leader with more than 27 years of senior executive experience in biotech companies and healthcare investment banking. Throughout his career, he has focused on capital raising, partnering and licensing deals, acquisitions, as well as overseeing p
Leading Antibody Discovery Technologies Enable Development of Innovative Therapeutics Regular-way Trading of OABI Begins November 2, 2022 on Nasdaq OmniAb, Inc. (NASDAQ:OABI) today announced the completion of the expected tax-free spin-off from Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and the subsequent business combination with Avista Public Acquisition Corp. II (NASDAQ:AHPA), resulting in OmniAb becoming an independent publicly traded company. Based on actual redemptions and estimated transaction expenses, OmniAb expects to have approximately $95 million in cash at closing. OmniAb will begin regular-way trading November 2, 2022 on Nasdaq under the stock ticker symbol "OABI." "
LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the appointment of Paul Maier as Non-Executive Director of the Board. Mr Maier will also be a member of 4D's Audit and Risk Committee and will serve as the Company’s “audit committee financial expert” under SEC and Nasdaq rules. “With over 25 years of extensive senior operational, international and financial management experience in the pharmaceutical and biotechnology industry, Paul will be able to provide 4D pharma with invaluable insights as we continue to execute
SCHEDULE 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)
10-Q - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)